Zika virus vaccine: The current state of affairs and challenges posed by antibody-dependent enhancement reaction

• Main Authors: Cheong, Heng Choon, Cheok, Yi Ying, Chan, Yee Teng, Sulaiman, Sofiah, Looi, Chung Yeng, Alshanon, Ahmed F., Hassan, Jamiyah, Abu Bakar, Sazaly, Wong, Won Fen
• Format: Article
• Published: Mary Ann Liebert, Inc 2022
• Subjects: QR Microbiology; RA Public aspects of medicine
• Online Access: http://eprints.um.edu.my/40374/

Infection caused by the Zika virus (ZIKV) can lead to serious neurological complications such as microcephaly in neonates. At present, no approved ZIKV vaccine is available, but few vaccine candidates are undergoing clinical trial. One major challenge faced is antibody-dependent enhancement (ADE) reaction that may provoke severe outcome in subsequent infection by ZIKV or other flaviviruses. Thus, more efforts should be dedicated to understanding ADE in designing a safe and effective vaccine to minimize the consequence of the potentially fatal infection's complications and to tackle potential ZIKV reemergence. This review discusses different types of ZIKV vaccine candidates that are currently underway in various stages of preclinical and clinical evaluations.